ENVALITH
イノバセル株式会社 logo

Innovacell Inc.

504A・Growth Market・Pharmaceuticals

イノバセル株式会社 logo
Innovacell Inc.504A

Business

Innovacell Inc. (single segment) is an R&D-driven biotech venture engaged in the development and commercialization of cell therapy products using autologous cells derived from human skeletal muscle. Established in Japan in January 2021, the company has over 20 years of R&D track record through its Austrian subsidiary Innovacell GmbH, founded in 2000. It currently focuses on three pipelines: urge fecal incontinence (ICEF15), passive fecal incontinence (ICEF16), and stress urinary incontinence (ICES13), with the lead program ICEF15 currently undergoing a Phase III international joint clinical trial (Fidelia study) in Japan and Europe. The company targets three markets—Japan, Europe, and the United States—and estimates the target patient population for urge fecal incontinence at approximately 120,000 in Japan, 430,000 in Europe, and 320,000 in the United States. The company listed on the TSE Growth Market in February 2026.

Business Model

The company adopts a "Cell Therapy/Regenerative Medicine Global Aggregation Model," through which it globally discovers, develops, and commercializes promising seeds. Following regulatory approval, the company anticipates seven types of revenue sources: product wholesale revenue, product sales revenue, upfront payments upon contract signing, development collaboration fees, milestone revenue, royalty revenue, and contract manufacturing revenue. In Japan, the company has already concluded an exclusive wholesale distribution agreement with Alfresa, while in Europe and the US, it is in the process of finalizing a term sheet with a commercialization services company. At present, no business revenue from external customers has been generated, and research and development funding is being covered through equity financing and venture debt from the European Investment Bank.

Company Strengths

Subsidiary Innovacell GmbH has continuously conducted R&D on skeletal muscle-derived cell therapy since its establishment in 2000. For ICEF15, the company has completed Phase I/II and late-stage Phase II trials (the STEFFI trial, 237 cases), with results published in multiple peer-reviewed academic journals. The therapy is also cited in the 2024 edition of the Fecal Incontinence Clinical Practice Guidelines (Japanese Society of Coloproctology), establishing its scientific credibility.

Innovacell GmbH owns its own GMP manufacturing facility and, in September 2022, became the first facility outside Asia to obtain "Specified Cell Processing Product Manufacturing Certification" from Japan's Ministry of Health, Labour and Welfare. The company has also raised EUR 15 million in venture debt from the European Investment Bank, demonstrating confidence from public institutions. All investigational products are manufactured at this facility.

Currently, there are no approved competing products similar to the company's pipeline in Japan, the US, or Europe. Other products under development in the market are all at an earlier development stage than the company's, making it highly likely that ICEF15 will be the first to reach the market. It is also described as "anal sphincter regeneration therapy" in the 2024 edition of Japan's Fecal Incontinence Clinical Practice Guidelines.

ENVALITH's Perspective

As of the end of March 2026, the number of randomized patients stood at 222 against a target of 290, with enrollment still in progress; the timing of enrollment completion will determine the approval application schedule. Whether recruitment promotion measures conducted in collaboration with the CRO prove effective is the most critical short-term monitoring indicator. Confirmation of accelerated enrollment could serve as a trigger for share price appreciation, while delays carry the risk of additional development cost recognition.

Operating loss for the first quarter of FY2026 (ending December 2026) was ¥723 million (of which R&D expenses were ¥517 million), representing a progress rate of 21.7% against the full-year operating loss forecast of ¥3,337 million. Business revenue remains zero, with expenses consisting solely of R&D expenses and general administrative expenses. Cash and deposits following the listing stood at a healthy ¥11,646 million, easing near-term concerns about cash flow, but a scenario requiring additional fundraising prior to obtaining approval cannot be ruled out.

Even after full repayment of the EIB venture debt, the present value of expected future payments under the associated royalty agreement is recorded as long-term borrowings (¥1,565 million). This estimate is based on future sales plans and other assumptions, and changes in these underlying assumptions could have a material impact on the financial statements in subsequent quarters. As an external factor, foreign exchange fluctuations have also affected ordinary loss (a foreign exchange loss of ¥18 million was recorded), and given the business structure's high proportion of euro-denominated transactions, a weaker yen would be a factor increasing expenses.

Growth Strategy

Prioritizing regulatory approval of ICEF15 across Japan, Europe, and the US as the top priority, while advancing next-generation pipeline development in parallel

A Phase III international multicenter trial that has been underway since 2022. As of the end of March 2026, 222 patients had been randomized and 191 transplants completed. The company plans to accelerate enrollment through a review of participating sites in collaboration with the CRO and patient recruitment advertising. Achieving the target of 290 patients is a prerequisite for filing for approval.

The listing was completed on February 24, 2026. The company raised ¥11,750 million through a public offering and third-party allotment, and fully repaid the EIB venture debt (principal and interest totaling approximately ¥3,212 million). Net assets turned positive and the equity ratio reached 79.1%, resolving the material event relating to the going concern assumption.

An exclusive wholesale distribution agreement for Japan has been concluded with Alfresa. The strategy is to establish the distribution and sales framework ahead of approval in order to shorten the lead time from approval to monetization.

The company is proceeding with confirmation of its development policy through Type B/C Meetings with the US FDA, aiming to expand into a tri-regional framework covering Japan, the US, and Europe. The US market represents the largest upside scenario, but the timing of realization remains uncertain and depends on the clinical trial and review schedule.

A term sheet has been signed with a European commercialization services company. The company plans to establish a sales and distribution framework following approval in Europe, accelerating monetization on a global basis.

The company is preparing to commence Phase I/II clinical trials for ICEF16 in 2026. Through the development of this next-generation product following ICEF15, the company aims to diversify its pipeline and enhance long-term corporate value.

Last updated: July 17, 2026